PHASQ Stock Crashes 99% on Pink Sheets, Bankruptcy Aftermath

PHASQ stock has collapsed to near-zero levels, trading at just $0.000001 USD on the Pink Sheets (PNK) exchange. The PHASQ stock price reflects the devastating aftermath of PhaseBio Pharmaceuticals’ Chapter 11 bankruptcy filing in October 2022. Once a clinical-stage biopharmaceutical company developing cardiovascular treatments, PhaseBio has seen its market value evaporate entirely. The company’s lead candidate, bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor, never reached commercialization. Today, PHASQ stock represents one of the market’s most severe equity collapses, with a 99% decline from its $0.0399 year-high.

The Collapse of PHASQ Stock and Bankruptcy Impact

PhaseBio Pharmaceuticals filed for voluntary Chapter 11 reorganization in the U.S. Bankruptcy Court for the District of Delaware on October 23, 2022. This filing marked the end of the company’s public equity value. PHASQ stock now trades on the Pink Sheets, a venue for distressed and delisted securities.

The company’s previous close price of $0.0001 has plummeted further to $0.000001, representing a staggering 99% single-day decline. Year-to-date performance shows consistent deterioration, with PHASQ stock down 99.99% over the past year. Trading volume remains extremely thin at just 2,500 shares, compared to an average volume of 22,310 shares. This minimal liquidity makes PHASQ stock highly illiquid and difficult to trade.

Financial Metrics Show Severe Distress

PHASQ stock’s financial fundamentals reveal a company in complete financial distress. The company reports negative earnings per share of -$2.14, with a price-to-earnings ratio that is mathematically meaningless at -4.67. Operating cash flow per share stands at -$1.61, indicating the company burns cash rapidly without revenue generation.

Book value per share is deeply negative at -$3.16, suggesting shareholders have negative equity positions. The company’s market capitalization is effectively zero, with no enterprise value. Free cash flow per share of -$1.70 demonstrates ongoing operational losses. These metrics confirm PHASQ stock holders face total equity wipeout in any bankruptcy resolution.

Pipeline Failure and Clinical Development Setbacks

PhaseBio’s lead product, bentracimab (PB2452), was designed as a reversal agent for ticagrelor-related bleeding events. The drug remained in Phase III clinical trials but never achieved regulatory approval or commercialization. Secondary candidates PB1046 for pulmonary arterial hypertension and PB6440 for resistant hypertension also failed to advance.

The company had a co-development agreement with SFJ Pharmaceuticals X, Ltd., but this partnership could not prevent the company’s collapse. Without approved products generating revenue, PhaseBio exhausted its cash reserves. The clinical-stage model proved unsustainable without successful trial outcomes or funding. PHASQ stock investors lost their entire investment as the pipeline failed to deliver.

Market Sentiment and Trading Activity

Trading Activity: PHASQ stock shows virtually no trading interest, with volume at 2,500 shares representing just 11% of average daily volume. The bid-ask spread is likely extremely wide, making execution nearly impossible for retail investors. Day low and day high both sit at $0.000001, indicating no price movement despite minimal trades.

Liquidation: Pink Sheets trading reflects the final stage of equity liquidation. Shareholders holding PHASQ stock face potential total loss in bankruptcy proceedings. The company’s 600 full-time employees were likely terminated or reassigned during reorganization. Any recovery for equity holders depends entirely on bankruptcy court decisions and asset sales, which historically favor creditors over common shareholders.

Final Thoughts

PHASQ stock collapsed following PhaseBio Pharmaceuticals’ October 2022 bankruptcy. Trading at $0.000001 on Pink Sheets with minimal liquidity, the stock lost 99% of its value after failed clinical trials, including lead candidate bentracimab. Meyka AI rates it C+. Shareholders face total loss in bankruptcy proceedings. This demonstrates the extreme risk of clinical-stage biotech investments where pipeline failures can eliminate equity value entirely.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.